Advertisement

Risk-Adapted Treatment for Acute Lymphoblastic Leukemia: Findings from St. Jude Children’s Research Hospital

  • C.-H. Puil
  • G. K. Rivera
  • M. L. Hancock
  • J. T. Sandlund
  • R. C. Ribeiro
  • J. M. Boyett
  • M. V. Relling
  • W. E. Evans
  • W. M. Crist
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 38)

Abstract

Data from St. Jude Total Therapy Study XI were analyzed to identify clinical and biologic features with prognostic significance. Results of this analysis, along with information available in the literature, led us to redefine lower-risk acute lymphoblastic leukemia (ALL) by the following features: DNA index between 1.16 and 1.60, or age 1-9 years plus white blood cell count (WBC)<50 x 109/1; absence of CNS leukemia, testicular leukemia, T-cell immunophenotype, and adverse genetic features (i.e., BCR-ABL [t(9; 22)], ALL-1-AF4 [t(4; 11)], or E2APBX1 [t(l; 19) in pre-B ALL]); and < 5% leukemic blasts in bone marrow aspirate on day 15 of remission induction. Based on these criteria, approximately 50% of newly diagnosed ALL cases would be classified to have lower-risk leukemia, and their projected long-term event-free survival approaches 90%. This new classification schema is being applied in our current risk-adapted clinical protocol for ALL (Study XIIIB).

Keywords

Acute Lymphoblastic Leukemia Central Nervous System Relapse Childhood Acute Lymphoblastic Leukemia Pediatric Oncology Group Continuation Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pui C-H, Crist WM (1994) Biology and treatment of acute lymphoblastic leukemia. J Pediatr 124: 491–503PubMedCrossRefGoogle Scholar
  2. 2.
    Pui C-H, Crist WM. Treatment of childhood leukemias. Current Opinion on Oncology (in press).Google Scholar
  3. 3.
    Pui C-H. Childhood leukemias. N Engl J Med ( in press).Google Scholar
  4. 4.
    Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui C-H, Abromowitch M, Mirro J Jr, Ochs JS, Look AT, Willimas DL, Murphy SB, Dahl GV, Kalwinsky DK, Evans WE, Kun Le, Simone JV, Crist WM (1991) Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337: 61–66PubMedCrossRefGoogle Scholar
  5. 5.
    Smith M (1994) Toward a more uniform approach to risk-classification and treatment assignment for children with acute lymphoblastic leukemia (ALL). ASCO Educational Book, pp 124-130.Google Scholar
  6. 6.
    Mahmoud HH, Rivera GK Hancock ML, Krance RA, Kun LE, Behm FG, Ribeiro RC, Sandlund JT, Crist WM, Pui C-H (1993) Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J med 329: 314–319PubMedCrossRefGoogle Scholar
  7. 7.
    Gilchrist GS, Tubergen DG, Sather HN, Coccia PF, O’Brien RT, Waskerwitz MJ, Hammond GD (1994) Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Childrens Cancer Group report. J’ Clin Oncol 12: 2594–2600Google Scholar
  8. 8.
    Mahmoud H, Relling M, Lie Q, Evans W, Kun L, Head D, Furman W, Ribeiro R, Kalwinsky D, Rivera G, Crist W, Pui C-H (1994) Presence of leukemic blasts in cerebrospinal fluid (CSF) is predicitive of central nervous system (CNS) relapse in childhood lymphoblastic leukemia. Proc ASCO 13: 319Google Scholar
  9. 9.
    Lauer S, Shuster J, Krichner 0, Kiefer G, Pullen J, Camitta B, Land V, Pediatric Oncology Group (POG) (1994) Prognostic significance of cerebrospinal fluid (CSF) lymphoblasts (LB) at diagnosis (dx) in children with lymphoblastic leukemia (ALL). Proc ASCO 13:317Google Scholar
  10. 10.
    Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE (1994) Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Insitute/Children’s Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12: 740–747PubMedGoogle Scholar
  11. 11.
    Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H (1994) Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122–3133PubMedGoogle Scholar
  12. 12.
    Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, Mahmoud H, Crist WM, Pui C-H, Evans WE (1994) Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94: 1996–2001PubMedCrossRefGoogle Scholar
  13. 13.
    Pui C-H, Crist WM, Look AT (1990) Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 76: 1449–1463PubMedGoogle Scholar
  14. 14.
    Trueworthy R, Shuster J, Look T, Crist W, Borowitz M, Carroll A, Frankel L, Harris M, Wagner H, Haggard M, Mosijczuk A,. Pullen J, Steuber P, Land V (1992) Ploidy of lymphoblasts is the strongest predictor of treatment outcome in Bprogenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 10: 606–613PubMedGoogle Scholar
  15. 15.
    Whitehead VM, Vuchich M-J, Carroll AJ, Lauer SJ, Mahoney D, Shuster JJ, Payment C, Koch PA, Akabutu JJ, Bowen T, Kamen BA, Ravindranath Y, Emami A, Beardsley GP, Pullen DJ, Camitta B (1994) Accumulation of methotrexate polyglutamates (MTXGPS) in lymphoblasts, ploidy and trisomy of both chromosomes 4 and 10 in childhood B-progenitor cell acute lymphoblastic leukemia (ALL): a Pediatric Oncology Group study. Blood 84(Suppl 1): 515aGoogle Scholar
  16. 16.
    Campana D, Kumagai M, Manabe A, Murti KG, Behm FG, Mahmoud H, Raimondi SC (1993) Hyperdiploid acute lymphoblastic leukemia (ALL): a distinct biological entity with marked propensity to programmed cell death. Blood 82(Suppl 1): 49aGoogle Scholar
  17. 17.
    Fletcher JA, Tu N, Tantravahi R, Sallan SE (1992) Extremely poor prognosis of pediatric acute lymphoblastic leukemia with translocation (9; 22): updated experience. Leukemia and Lymphoma 8: 75–79PubMedCrossRefGoogle Scholar
  18. 18.
    Pui C-H, Frankel LS, Carroll AJ, Raimondi SC, Shuster JJ, Head DR, Crist WM, Land VJ, Pullen DJ, Steuber CP, Behm FG, Borrowitz MJ (1991) Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23):a collaborative study of 40 cases. Blood 77: 440–447PubMedGoogle Scholar
  19. 19.
    Roberts WM, Rivera GK, Raimondi SC, Santana VM, Sandlund JT, Crist WM, Pui C-H (1994) Intensive chemotherapy for Philadelphia-chromosome-positive acute lymphoblastic leukaemia. Lancet 343:331–332PubMedCrossRefGoogle Scholar
  20. 20.
    Pui C-H, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH, Sandlund JT, Crist WM, Behm FG (1994) Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(l; 19) (q23; p13) or its derivative. J Clin Oncol 12: 2601–2602.PubMedGoogle Scholar
  21. 21.
    Pui C-H, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribeiro RC, Head DR, Mahmoud HH, Sandlund JT, Furman WL, Roberts WM, Crist WM, Raimondi SC (1994) 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 12: 909–915PubMedGoogle Scholar
  22. 22.
    Miller DR, Coccia PF, Bleyer WA, Lukens JN, Siegel SE, Sather HN, Hammond GD (1989) Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol 7: 1807–1815PubMedGoogle Scholar
  23. 23.
    Veerman AJ, Hählen K, Kamps WA, Vanleeuwen EF, deVaan GA, Vanwering ER, Vanderdoes-Vandenberg A, Solbu G, Suciu S (1990) Dutch Childhood Leukemia Study Group: early results of Study ALL VI (1984-1988). Haematol Bluttransfus 33:473–477Google Scholar
  24. 24.
    Pui C-H, Simone JV, Hancock ML, Evans WE, Williams DL, Bowman WP, Dahl GV, Dodge RK, Ochs J, Abromowitch M, Rivera GK (1992) Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: longterm results of St. Jude Total Therapy Study X. Leukemia 6: 150–157PubMedGoogle Scholar
  25. 25.
    Chessells JM, Bailey C, Richards SM, for the Medical Research Council Working Party on Childhood Leukemia (1995): Intensification of treatment and survival in all children with lymphoblastic leukemia: results of UK Medical Research Council trial UKALL X. Lancet 345: 143–148PubMedCrossRefGoogle Scholar
  26. 26.
    Pui C-H, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud HH, Sandlund JT, Crist WM (1991) Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325: 1682–1687PubMedCrossRefGoogle Scholar
  27. 27.
    Gajjar A, Ribeiro R, Hancock M, Rivera G, Mahmoud H, Sandlund J, Crist W, Pui C-H (1994) Persistence of circulating blasts after one week of intensive remission induction therapy confers a poor prognosis in childhood acute lymphoblastic leukemia (ALL). Blood 84 (Suppl 1): 515aGoogle Scholar
  28. 28.
    Kumagai M, Manabe A, Behm FG, Raimondi SC, Hancock M, Crist WM, Mahmoud H, Pui C-H, Campana D (1994) In vitro leukemic cell growth on stroma predicts outcome in childhood B-lineage acute lymphoblastic leukemia (ALL). Blood 84(Suppl 1): 516aGoogle Scholar
  29. 29.
    Okuda T, Valentine MB, Shurtleff SA, Hulshof MG, Komuro H, Raimondi SC, Pui C-H, Beach D, Sherr CJ, Look AT, Downing JR (1994) Frequent deletion of INK4a/MTSl in periatric acute lymphoblastic leukemia. Blood 84 (Suppl 1): 298aGoogle Scholar
  30. 30.
    Hebert J, Cayuela JM, Berkeley J, Sigaux F (1994) Candidate tumor-suppressor genes MTS1 (pl6 INK4A ) and MTS2 (pl5 INK4B ) display frequent homozygous deletion in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 84: 4038–4044PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • C.-H. Puil
    • 1
    • 4
    • 5
  • G. K. Rivera
    • 1
    • 5
  • M. L. Hancock
    • 2
  • J. T. Sandlund
    • 1
    • 5
  • R. C. Ribeiro
    • 1
    • 3
  • J. M. Boyett
    • 2
  • M. V. Relling
    • 3
    • 5
  • W. E. Evans
    • 3
    • 5
  • W. M. Crist
    • 1
    • 5
  1. 1.Department of Hematology-OncologySt. Jude’s Children’s Research HospitalMemphisUSA
  2. 2.Department of BiostatisticsSt. Jude’s Children’s Research HospitalMemphisUSA
  3. 3.Department of Pharmaceutical ScienceSt. Jude Children’s Research HospitalMemphisUSA
  4. 4.Department of Pathology and Laboratory MedicineSt. Jude Children’s Research HospitalMemphisUSA
  5. 5.Memphis, College of MedicineUniversity of TennesseeMemphisUSA

Personalised recommendations